Trial Profile
Randomized phase II trial comparing amrubicine/irinotecan with cisplatin/irinotecan in patients with extensive-stage small-cell lung cancer: (JMTO LC 08-01) .
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Cisplatin; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.
- 14 Jul 2014 According to the University Hospital Medical Information Network - Japan, status changed from recruiting to active, no longer recruiting.
- 14 Jul 2012 Additional lead trial centre (Japan-multinational Trial Organization) added as reported by University Hospital Medical Information Network - Japan.